🇺🇸 FDA
Pipeline program

RO7790121 placebo, RO7790121

WA45846

Phase 2 small_molecule active

Quick answer

RO7790121 placebo, RO7790121 for Moderate to Severe Rheumatoid Arthritis (RA) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Roche Registration Limited
Indication
Moderate to Severe Rheumatoid Arthritis (RA)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials